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Boston and Framingham, MassachusettsOBJECTIVES The aim of this study was to evaluate whether computed tomography (CT) attenua-
tion, as a measure of fat quality, is associated with cardiometabolic risk factors above and beyond fat
quantity.
BACKGROUND Visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) are pathogenic
fat depots associated with cardiometabolic risk. Adipose tissue attenuation in CT images is variable,
similar to adipose tissue volume. However, whether the quality of abdominal fat attenuation is associated
with cardiometabolic risk independent of the quantity is uncertain.
METHODS Participants were drawn from the Framingham Heart Study CT substudy. The VAT and
SAT volumes were acquired by semiquantitative assessment. Fat quality was measured by CT attenuation
and recorded as mean Hounsﬁeld unit (HU) within each fat depot. Sex-speciﬁc linear and logistic
multivariable regression models were used to assess the association between standard deviation (SD)
decrease in HU and each risk factor.
RESULTS Lower CT attenuation of VAT and SAT was correlated with higher body mass index levels in
both sexes. Risk factors were generally more adverse with decreasing HU values. For example, in women,
per 1 SD decrease in VAT HU, the odds ratio (OR) was increased for hypertension (OR: 1.80), impaired
fasting glucose (OR: 2.10), metabolic syndrome (OR: 3.65), and insulin resistance (OR: 3.36; all p <
0.0001). In models that further adjusted for VAT volume, impaired fasting glucose, metabolic syndrome,
and insulin resistance remained signiﬁcant. Trends were similar but less pronounced for SAT and for men.
There was evidence of an interaction between HU and fat volume among both women and men.
CONCLUSIONS Lower CT attenuation of VAT and SAT is associated with adverse cardiometabolic
risk above and beyond total adipose tissue volume. Qualitative indices of abdominal fat depots may
provide insight regarding cardiometabolic risk independent of fat quantity. (J Am Coll Cardiol Img
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763besity is a heterogeneous condition with
individual variability in both fat depositionA B B R E V I A T I O N S
A N D A C R O N YM S
BMI = body mass index
CT = computed tomography
FPG = fasting plasma glucose
HDL = high-density lipoprotein
HOMA-IR = homeostatic model
assessment insulin resistance
HU = Hounsﬁeld unit
MDCT = multidetector
computed tomography
OR = odds ratio
SAT = subcutaneous adipose
tissue(1) and associated metabolic complications
(2). In addition, different fat depots are
associated with differential metabolic risk (1,3,4).
Visceral adipose tissue (VAT) in particular is
considered to be a unique pathogenic fat depot (1,3).
Most fat-distribution studies thus far have focused on
the absolute volume of adipose tissue in any given
depot (1,3,5). However, several lines of experimental
evidence suggest that measures of fat quality may also
be important. These studies have predominantly
focused on cellular characteristics of fat depots
including adipocyte size (6–10), macrophage accu-
mulation (8,11–14), arteriolar dysfunction (12,14),
angiogenesis (15), and cellular hypoxia (10) as related
to metabolic risk. However, the majority of these fat-
quality parameters are only directly measurable by
biopsy and invasive procedures.
Radiographic imaging can be exploited to provide
information about adipose tissue quality in addition to
volume. Computed tomography (CT) imaging uses a
quantitative scale for describing radiodensity, referred
to as Hounsﬁeld units (HU), which are based on
radiographic pixels and are used to differentiate tissue
subtypes with negative HU in the range of 195
to45, the range typically attributed to fat (16). Small,
experimental studies in animal models have demon-
strated that lower HU is associated with adipose tissue
that contains higher levels of lipid content (17), a
radiologic ﬁnding that has also been clinically assessed
in a small pediatric population (18). Fat depots with
higher lipid content and lipolytic activity can increase
systemic free fatty acids (19), which can inducemuscleFigure 1. Visceral and Subcutaneous Adipose Tissue on
Computed Tomography
For this scan, computer-generated Hounsﬁeld units (HU) for
visceral adipose tissue (VAT) was 99.8, and for subcutaneous
adipose tissue (SAT) it was 109.4.(20) and hepatic insulin resistance (21) in addition to
endothelial dysfunction (22).
Given this framework, we hypothesized that the
quality of adipose tissue characterized by HU would
be associated with metabolic risk independent of
overall adipose tissue volume. More speciﬁcally, we
hypothesized that lower CT attenuation would be
associated with an adverse metabolic proﬁle. If so,
these ﬁndings may provide a unique, novel framework
by which to interpret CT imaging of fat depots and
may potentially add to our understanding of the het-
erogeneity of clinical outcomes associatedwith obesity.
METHODS
Study participants. Participants for the present
study were drawn from the Framingham Heart
Study, which began enrollment of the original cohort
in 1948 (23). In 1971, offspring of the originalVAT = visceral adipose tissuecohort and their spouses were enrolled in
the offspring cohort (24) and in 2002,
children of the offspring cohort participants
were recruited for the third-generation
cohort (25). Data for the present study
were drawn from offspring and third-gen-
eration cohort participants who have previ-
ously undergone multidetector computed
tomography (MDCT) as a substudy in the
Framingham Heart Study. A total of 3,394
participants (1,400 from offspring and 1,994
from third generation) underwent MDCT
scanning from 2002 to 2005. Participants
with missing covariate and outcomes data
were excluded, resulting in a ﬁnal sample
size of 3,198 subjects in our analysis. The
average amount of time that passed between MDCT
completion and the visit examination at which the risk
factors were assessed was 1.7 years.
Measurement of SAT and VAT. Participants under-
went 8-slice MDCT scanning of the abdomen in a
supine position. Twenty-ﬁve contiguous 5-mm
slices were obtained, with an average radiation
dose of 3 mSv to 5 mSv. Subcutaneous and visceral
adipose tissue volumes were acquired by manually
outlining the abdominal muscular wall separating
the visceral from the subcutaneous fat depots. Fat
was deﬁned as any voxel between 195 HU to
45 HU. We recorded the average HU of each fat
depot (Fig. 1). In previous work by our group,
evaluation of this technique has produced high
inter-reader and intrareader correlation (0.997 for
SAT, 0.992 for VAT) (16). To evaluate the vari-
ability within each depot, we manually traced 1-cm2
regions of interest in 12 anatomically distinct
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tissue in 25 randomly selected participants in our
dataset. We evaluated these regions in 3 slices per
individual scan. The average standard deviation
within SAT was 7.6 HU, and within VAT it was
5.5 HU, suggesting modest variability of the
Hounsﬁeld unit measurement within each fat depot.
Metabolic risk factors. Body mass index (BMI) was
calculated by weight (kilograms) divided by the
square of height (meters). Weight was assessed using
a Detecto scale (Webb City, Missouri) in clinic.
Waist circumference was completed at the level of the
umbilicus and measured to the nearest 0.25 inch.
Blood pressure was measured at rest twice using a
mercury column sphygmomanometer; hypertension
was deﬁned as systolic blood pressure$140 mmHg,
diastolic blood pressure $90 mm Hg, or the use of
hypertensive medications. Fasting plasma glucose
(FPG) was collected; impaired fasting glucose was
deﬁned as an FPG level of 100 to 125 mg/dl in
participants not treated for diabetes, and diabetes
mellitus was deﬁned as an FPG $126 mg/dl or
treatment with insulin or an oral hypoglycemic agent.
Metabolic syndrome was deﬁned based on the
modiﬁed Adult Treatment Panel III criteria (26).
Insulin was measured using radioimmunoassay in the
offspring cohort, and enzyme-linked immunosorbent
assay in the third-generation cohort. For the
offspring cohort, the intra-assay coefﬁcient of varia-
tion for insulin was 3.9%, and the interassay coefﬁ-
cient of variation had a range of 4.7% to 6.1% (27).
For the third-generation cohort, the intra-assay
coefﬁcient of variation for insulin was 2.7%, and the
interassay coefﬁcient of variation was 8.1% (27). Due
to the differing methods used to measure insulin in
the 2 cohorts, all values for the third-generation
cohort were standardized to those for the offspring
cohort, as previously described (27). Total choles-
terol, high-density lipoprotein (HDL) cholesterol,
and triglycerides were also measured on the fasting
plasma sample. Homeostatic model assessment in-
sulin resistance (HOMA-IR)was calculated based on
FPG and insulin levels, as previously described (28).
Insulin resistance was deﬁned by a HOMA-IR
$75th percentile in subjects free of diabetes.
Measurement of covariates. Participants were con-
sidered current smokers if they had smoked at
least 1 cigarette per day during the previous year. A
series of physician-administered questions assessed
alcohol use and dichotomized participants on the
basis of consumption of >14 drinks per week (men)
or >7 drinks per week (women). Physical activity
was assessed on the basis of a questionnaire
capturing average daily number of hours of sleep andsedentary, slight, moderate, and heavy activity of the
participant. Women were classiﬁed as menopausal if
they were without menstrual bleeding for $1 year.
Statistical analysis. Mean visceral HU and subcu-
taneous HU were approximately normally distrib-
uted and untransformed data were used for analysis.
Triglycerides were log-transformed to improve the
normality of the distribution. Age-adjusted, sex-
speciﬁc Pearson correlation coefﬁcients were calcu-
lated to assess the correlations between mean HU
and continuous cardiometabolic risk factors.
Multivariable-adjusted linear regression models
were constructed to assess the association per 1 SD
decrement in visceral and subcutaneous HU and
continuous risk factors; multivariable-adjusted lo-
gistic regression models were performed for dichot-
omous outcomes. As previous research has identiﬁed
sex differences (3) among results, all analyses were
stratiﬁed by sex. For each outcome, 3 models were
run. The ﬁrst model adjusted for age, current
smoking status, alcohol use, physical activity, and
lipid and blood pressure lowering medications.
Menopausal status and hormone replacement ther-
apy were also included as covariates in models among
women. The second model included the same cova-
riates from model 1 as well as BMI. In model 3, we
adjusted for the covariates in model 1 as well as adi-
pose tissue volume (VAT or SAT, respectively).
Additional analyses investigated interactions be-
tween mean HU and VAT or SAT. Further ana-
lyses tested interactions between HU and both age
and sex. We evaluated the association between
cardiometabolic risk factors and tertiles of HU
across tertiles of VAT volume.
All analyses were performed using SAS version
9.2 (SAS Institute, Cary, North Carolina). All
p values <0.05 were considered statistically signiﬁ-
cant for all analyses.
RESULTS
Characteristics of the 3,198 study participants are
presented in Table 1. The sample was 47% women.
The mean age was 51.9 years for women and
49.6 years for men. The mean SAT HU values were
102.3  5.1 for women and 99.6  4.5 for men.
The mean VAT HU values were 92.4  4.4 for
women and 95.2  4.5 for men. Both SAT HU
and VAT HU were statistically different between
men and women (p < 0.0001).
Pearson correlation coefﬁcients. Visceral and sub-
cutaneous HU values were inversely correlated with
all cardiometabolic risk factors in both men and
women (Table 2). For example, VAT HU was
Table 1. Study Sample Characteristics
Women
(n [ 1,518)
Men
(n [ 1,680)
Continuous characteristics
Age, yrs 51.9  9.8 49.6  10.6
BMI, kg/m2 27.0  5.8 28.4  4.5
Waist circumference, cm 93.0  15.5 100.8  11.8
VAT, cm3 1,353  832 2,226  1,020
SAT, cm3 3,134  1,510 2,633  1,207
VAT, HU 92.4  4.4 95.2  4.5
SAT, HU 102.3  5.1 99.6  4.5
FPG mg/dl 95.8  18.1 102.1  23.7
HOMA-IR* 2.7  1.3 3.1  1.5
SBP, mm Hg 120.1  17.6 123.3  14.6
DBP, mm Hg 73.6  9.2 78.0  9.0
HDLC, mg/dl 61.3  16.9 45.9  12.4
TG, mg/dl 93 (66, 139) 115 (77, 174)
Categorical characteristics
Hypertension 401  26.4 523  31.1
Diabetes mellitus 82  5.4 121  7.2
Hypertension treatment 282  18.6 317  18.9
Diabetes treatment 44  2.9 59  3.5
Lipid treatment 155  10.2 295  17.6
Metabolic syndrome 410  27.0 631  37.6
Insulin resistance*y 334  25.4 402  27.4
Current smoking 184  12.1 225  13.4
Alcohol usez 226  14.9 269  16.0
Post-menopausal 760  50.1 NA
Current hormone replacement therapy 292  19.2 NA
Values are mean  SD or median (quartile 1, quartile 3). *Among nondiabetes participants with available
homeostatic model assessment–insulin resistance (HOMA-IR) data. yDeﬁned as a HOMA-IR $75th
percentile. zDeﬁned as >14 drinks per week for men or >7 drinks per week for women.
DBP ¼ diastolic blood pressure; FPG ¼ fasting plasma glucose; HDLC ¼ high-density lipoprotein
cholesterol; HU ¼ Hounsﬁeld units; NA ¼ not applicable; SAT ¼ subcutaneous adipose tissue; SBP ¼
systolic blood pressure; TG ¼ triglycerides; VAT ¼ visceral adipose tissue.
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765inversely correlated with BMI in women (r¼0.51,
p < 0.001) and men (r ¼ 0.42, p < 0.001) and
inversely correlated with VAT volume in women
(r ¼ 0.75, p < 0.001) and men (r ¼ 0.72,
p< 0.001). Similar results were observed for SATHU.
Quality of VAT. Table 3 presents the association
of risk factors per 1-SD decrement in VAT HU.
Among both women and men, VAT HU was
associated with all risk factors (p < 0.001) after
multivariable adjustment. After further adjustment
for BMI, associations between VAT HU and sys-
tolic blood pressure (p < 0.0001), diastolic blood
pressure (p < 0.0001), fasting glucose (p < 0.0001),
log HOMA-IR (p < 0.0001), log triglycerides
(p < 0.0001), and HDL (p < 0.0001) remained
signiﬁcant in both women and men. After adjust-
ment for VAT volume, VAT HU remained asso-
ciated with diastolic blood pressure (p < 0.0001),
log HOMA-IR (p < 0.001), log triglycerides (p <
0.0001), and HDL (p ¼ 0.001) in both men and
women. For example, among women, a 1-SD
decrement in VAT HU was associated with a
2.27 mm Hg (p < 0.0001) higher diastolic blood
pressure. This association was attenuated but still
remained signiﬁcant upon adjustment for BMI
(1.52 mm Hg per 1-SD HU decrement, p <
0.0001) and absolute VAT volume (1.39 mm Hg per
1-SD HU decrement, p < 0.0001).
Table 4 presents the odds ratios (OR) for car-
diometabolic outcomes per 1-SD decrement in
VAT HU. Lower VAT HU was associated with
increased odds of hypertension (p < 0.0001),
impaired fasting glucose (p < 0.0001), metabolic
syndrome (p < 0.0001), and insulin resistance
(p < 0.0001) among both women and men. In
general, consistent associations were observed be-
tween VAT HU and outcomes even after adjust-
ment for BMI or VAT volumes, although the results
were somewhat attenuated. Results were generally
consistent with our a priori hypothesis of more
adverse associations with lower HU values, with the
exception of diabetes, where lower VAT HU levels
were associated with lower odds of diabetes.
Quality of SAT. Results for SAT HU and contin-
uous and dichotomous risk factors generally fol-
lowed patterns similar to that of VAT HU,
although the magnitude of association was some-
what weaker (Tables 3 and 4).
We observed paradoxical associations between
SAT HU and diabetes: a 1 SD SAT HU decrement
was associated with a lower OR for diabetes in both
women (OR: 0.76) and men (OR: 0.79). This as-
sociation persisted after further adjustment for BMI
and SAT volumes (all p < 0.001). Thus, weperformed secondary analyses in which we excluded
all subjects with diabetes treated with insulin (n ¼
12). The associations between SAT HU and both
diabetes and fasting glucose were not materially
different (data not shown).
Secondary analysis. Because of the possibility for
interaction between VAT and SAT HU with sex,
age, and/or absolute fat volume, we conducted
interaction testing. There was evidence of a sex
interaction with VATHU for systolic blood pressure
(p ¼ 0.002), FPG (p ¼ 0.0006), HDL (p ¼ 0.03),
impaired fasting glucose (p ¼ 0.0009), and diabetes
mellitus (p ¼ 0.01). For SAT, there was evidence of
an interaction between sex and SAT HU for systolic
blood pressure (p ¼ 0.04) and FPG (p ¼ 0.004). All
Table 2. Age-Adjusted Pearson Correlation Coefﬁcients Between
VAT HU and SAT HU and Cardiometabolic Risk, by Sex
VAT HU SAT HU
Women Men Women Men
BMI 0.51* 0.42* 0.30* 0.34*
Waist circumference 0.53* 0.44* 0.36* 0.42*
SAT 0.51* 0.40* 0.49* 0.56*
VAT 0.75* 0.72* 0.36* 0.42*
Log insulin 0.42* 0.36* 0.15* 0.20*
Log HOMA-IR 0.48* 0.42* 0.23* 0.26*
FPG 0.22* 0.04 0.05y 0.06y
SBP 0.24* 0.18* 0.15* 0.08*
DBP 0.26* 0.28* 0.18* 0.17*
HDLC 0.34* 0.36* 0.16* 0.17*
Log triglycerides 0.40* 0.38* 0.26* 0.19*
*p < 0.001. yp < 0.05.
Abbreviations as in Table 1.
Rosenquist et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 7 , 2 0 1 3
Fat Quality and Cardiometabolic Risk J U L Y 2 0 1 3 : 7 6 2 – 7 1
766observed associations were stronger in women than
in men.With regard to age, the interactions between
age and VAT HU for systolic blood pressure (p ¼
0.01), diastolic blood pressure (p ¼ 0.0002), log
triglycerides (p < 0.0001), hypertension (p <
0.0001), metabolic syndrome (p < 0.0001), and log
HOMA-IR (p ¼ 0.002) were signiﬁcant. For SAT,
the interactions between age and SAT HU were
signiﬁcant for FPG (p¼ 0.02), log triglycerides (p¼
0.0009), HDL (p ¼ 0.03), and hypertension (p ¼
0.005). In general, most associations were stronger
in younger persons.
We also tested for an interaction between VAT
HU and VAT volume and between SAT HU and
SAT volume. The interaction between VAT HU
and VAT volume was statistically signiﬁcant for log
triglycerides, HDL, diabetes, metabolic syndrome,
and insulin resistance (p < 0.05 in women and men;
data not shown). FPG was also signiﬁcant in men
(p ¼ 0.002). Similarly, the interaction between
SAT HU and SAT volume was signiﬁcant for
diabetes (p < 0.0001), metabolic syndrome (p ¼
0.0001), and insulin resistance (p ¼ 0.01) in
women; and for FPG (p < 0.0001), log HOMA-IR
(p ¼ 0.01), log triglycerides (p ¼ 0.002), HDL (p ¼
0.03), and diabetes (p ¼ 0.007) in men. For SAT,
the overall trend suggested a stronger association
with a lower fat volume in both men and women.
Conversely, VAT demonstrated a stronger associa-
tion with higher fat volumes for women, but
not men.
Finally, we examined the associations of VAT
and SAT HU within tertiles of absolute levels ofVAT or SAT (Fig. 2, Online Fig. 1). Among
women, each lower tertile of VAT HU was asso-
ciated with more adverse levels of risk factors,
particularly for insulin resistance, low HDL, and
metabolic syndrome. Similar results were observed
in men. Results for SAT HU are shown in Online
Figure 1. Whereas similar trends were observed in
SAT compared to VAT for impaired fasting
glucose, we observed paradoxical associations, with
decreasing risk associated with decreased preva-
lences of insulin resistance, low HDL, metabolic
syndrome, and diabetes in women. General trends
were similar but less pronounced in men.
D I SCUSS ION
Our principal ﬁndings are 3-fold. First, lower CT
attenuation as measured in HU was associated with
adverse cardiometabolic risk. Second, these ﬁndings
persisted even after adjustment for generalized
adiposity (BMI) or absolute VAT or SAT volume.
Finally, we observed interactions between quality
and quantity of VAT and SAT for several car-
diometabolic risk factors, where persons with high
volumes of VAT and low HU had the most adverse
risk proﬁles. Taken together, these ﬁndings suggest
that quality of VAT and SAT is associated with
cardiometabolic risk above and beyond absolute
levels of fat volumes.
Overall, our results were consistent with our a
priori hypothesis. Lower CT attenuation was asso-
ciated with a more adverse metabolic proﬁle, with the
notable exception of diabetes. Diabetes, but not
impaired fasting glucose, demonstrated a paradoxical
association in that lower HU was associated with a
decreased risk of diabetes. This association was
particularly pronounced in association with SAT
HU. A secondary analysis showed that this associa-
tion was unlikely to be driven by a focal disruption of
SAT by insulin use, as the exclusion of these subjects
from analysis did not signiﬁcantly alter this trend. In
addition, as shown in Online Figure 1 lower SAT
HU was associated with a decreased risk of diabetes
within narrow ranges of SAT volume. Taken
together, these ﬁndings suggest that there may be
characteristic differences in fat quality of SAT depots
contributing to variable CT attenuation when
compared to VAT depots. In addition, these ﬁndings
appear unique in diabetes per se and are not associ-
ated with impaired fasting glucose alone. Recent
ﬁndings in the area of extracellular matrix remodel-
ing in adipose tissue may provide insights into our
results, as differences in collagen ﬁbrosis between
VAT and SAT have revealed more abundant levels
Table 3. Multivariable Linear Regression of Hounsﬁeld Units and Continuous Cardiometabolic Risk Factors
VAT HU SAT HU
Women
b (95% CI)
Women
p Value
Men
b (95% CI)
Men
p Value
Women
b (95% CI)
Women
p Value
Men
b (95% CI)
Men
p Value
SBP, mm Hg
Multivariable 3.46 (2.66 to 4.26) <0.0001 2.37(1.72 to 3.02) <0.0001 2.46 (1.67 to 3.25) <0.0001 1.15 (0.49 to 1.81) 0.0007
þBMI 1.93 (1.03 to 2.82) <0.0001 1.43 (0.73 to 2.14) <0.0001 1.44 (0.64 to 2.25) 0.0004 0.20 (-0.49 to 0.89) 0.57
þFat volume* 0.91 (0.26 to 2.09) 0.13 0.81 (0.12 to 1.74) 0.09 0.90 (0.01 to 1.78) 0.048 0.03 (-0.82 to 0.76) 0.94
DBP, mm Hg
Multivariable 2.27 (1.81 to 2.73) <0.0001 2.47 (2.05 to 2.88) <0.0001 1.56 (1.11 to 2.02) <0.0001 1.48 (1.05 to 1.91) <0.0001
þBMI 1.52 (1.01 to 2.04) <0.0001 1.93 (1.48 to 2.38) <0.0001 1.02 (0.56 to 1.49) <0.0001 0.87 (0.42 to 1.31) 0.0002
þFat volume* 1.39 (0.71 to 2.07) <0.0001 1.87 (1.27 to 2.47) <0.0001 0.67 (0.16 to 1.18) <0.01 0.74 (0.23 to 1.25) 0.005
FPG, mg/dl
Multivariable 3.64 (2.94 to 4.35) <0.0001 1.51 (0.50 to 2.51) 0.003 1.81 (1.09 to 2.53) <0.0001 0.23 (1.25 to 0.79) 0.66
þBMI 1.94 (1.15 to 2.74) <0.0001 0.39 (1.49 to 0.71) 0.49 0.59 (0.14 to 1.31) 0.11 2.04 (3.11 to 0.97) 0.0002
þFat volume* -0.11 (1.16 to 0.94) 0.84 2.06 (3.52 to 0.59) 0.006 0.03 (0.77 to 0.84) 0.94 2.25 (3.48 to 1.01) 0.0004
Log HOMA-IRy
Multivariable 0.19 (0.17 to 0.21) <0.0001 0.18 (0.16 to 0.19) <0.0001 0.09 (0.07 to 0.11) <0.0001 0.11 (0.09 to 0.13) <0.0001
þBMI 0.11 (0.09 to 0.14) <0.0001 0.10 (0.08 to 0.12) <0.0001 0.03 (0.01 to 0.05) 0.005 0.03 (0.01 to 0.05) 0.0053
þFat volume* 0.06 (0.03 to 0.09) <0.001 0.04 (0.01 to 0.06) 0.01 0.00 (0.02 to 0.03) 0.70 0.01 (0.01 to 0.03) 0.43
Log TG, mg/dl
Multivariable 0.20 (0.17 to 0.22) <0.0001 0.22 (0.19 to 0.24) <0.0001 0.12 (0.10 to 0.15) <0.0001 0.11 (0.08 to 0.14) <0.0001
þBMI 0.14 (0.11 to 0.17) <0.0001 0.19 (0.16 to 0.21) <0.0001 0.08 (0.06 to 0.10) <0.0001 0.06 (0.04 to 0.09) <0.0001
þFat volume* 0.07 (0.04 to 0.10) <0.0001 0.15 (0.12 to 0.19) <0.0001 0.06 (0.04 to 0.09) <0.0001 0.08 (0.05 to 0.11) <0.0001
HDLC, mg/dl
Multivariable 5.15 (5.95 to 4.36) <0.0001 4.36 (4.90 to 3.82) <0.0001 2.56 (3.37 to 1.74) <0.0001 2.01 (2.58 to 1.43) <0.0001
þBMI 3.50 (4.40 to 2.59) <0.0001 3.59 (4.17 to 3.01) <0.0001 1.27 (2.08 to 0.45) 0.002 0.98 (1.57 to 0.39) 0.001
þFat volume* 1.91 (3.09 to 0.74) 0.001 3.15 (3.92 to 2.38) <0.0001 0.77 (1.67 to 0.14) 0.1 1.22 (1.90 to 0.54) 0.0005
Values are beta coefﬁcients (ß) with 95% conﬁdence interval (CI) per 1-SD decrease in HU. Blood pressure indices were also adjusted for hypertension treatment; glycemic measures were also
adjusted for diabetes treatment; lipid indices were also adjusted for hyperlipidemia treatment. The p values for sex interaction for VAT HU: SBP (p¼ 0.002), DBP (p¼ 0.86), FPG (p¼ 0.0006), HOMA-IR
(p ¼ 0.23), TG (p ¼ 0.59), and HDLC (p ¼ 0.03). The p values for sex interaction for SAT HU: SBP (p ¼ 0.04), DBP (p ¼ 0.90), FPG (p ¼ 0.004), HOMA-IR (p ¼ 0.06), TG (p ¼ 0.93), and HDLC (p ¼ 0.47).
*VAT-HU regressions adjusted for VAT volume; SAT-HU regressions adjusted for SAT volume. yAmong nondiabetes participants with available HOMA-IR data.
Abbreviations as in Table 1.
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767of ﬁbrosis in SAT (29). In addition, ﬁbrosis in VAT
appears to limit adipocyte hypertrophy and is asso-
ciated with a more favorable lipid proﬁle, whereas
SAT ﬁbrosis appears metabolically maladaptive and
hampers efforts at weight loss (29). Higher level of
ﬁbrosis would be theoretically manifested by less
negative HUs and may in part help to explain this
paradoxical association with diabetes risk in SAT.
In the context of the current literature. Numerous
studies in the current literature have focused on
the quantiﬁcation of fat volumes in regard to car-
diometabolic risk (1,3,5). Many of these studies
have used CT imaging to determine the quantity of
fat as VAT or SAT volumes. The majority of these
studies, including work by our group (3), have found
that VAT volume in particular is associated with an
adverse cardiometabolic risk proﬁle when compared
to SAT (1,3,5,30–32).Few studies have utilized qualitative approaches to
study the association between ectopic fat depots and
cardiometabolic risk. The notion that fat quality, in
addition to quantity, can be an important determi-
nant of metabolic risk have typically been performed
using invasive fat biopsy techniques and have thus
been limited to small sample sizes and animal
models. For example, fat biopsy studies evaluating
adipocyte size have shown an inverse correlation
between mean adipocyte size and indicators of sys-
temic insulin resistance (7,9). Other studies in hu-
man fat tissue have focused on the vasculature and the
angiogenic potential of varying fat depots (10,15).
In a recent study of subcutaneous and visceral human
fat tissue, it was shown that the angiogenic potential
of fat tissue decreased with increasing BMI and
morbid obesity (15). Finally, there is an extensive
body of literature describing cellular mechanisms
Table 4. Multivariable Logistic Regression of Hounsﬁeld Units and Dichotomous Cardiometabolic Risk Factors
VAT HU SAT HU
Women
OR (95% CI)
Women
p Value
Men
OR (95% CI)
Men
p Value
Women
OR (95% CI)
Women
p Value
Men
OR (95% CI)
Men
p Value
Hypertension
Multivariable 1.80 (1.58–2.06) <0.0001 1.70 (1.50–1.93) <0.0001 1.21 (1.05–1.40) 0.0083 1.32 (1.16–1.50) <0.0001
þBMI 1.44 (1.24–1.68) <0.0001 1.46 (1.28–1.67) <0.0001 1.07 (0.91–1.25) 0.40 1.13 (0.99–1.29) 0.08
þFat volume* 1.15 (0.93–1.42) 0.19 1.20 (1.01–1.42) 0.04 0.96 (0.82–1.13) 0.63 1.04 (0.90–1.20) 0.63
Impaired FG
Multivariable 2.10 (1.80–2.44) <0.0001 1.58 (1.41–1.76) <0.0001 1.57 (1.30–1.89) <0.0001 1.36 (1.21–1.53) <0.0001
þBMI 1.74 (1.47–2.05) <0.0001 1.45 (1.29–1.64) <0.0001 1.45 (1.19–1.76) 0.0003 1.24 (1.10–1.39) 0.0006
þFat volume* 1.48 (1.18–1.85) 0.0006 1.34 (1.15–1.56) 0.0002 1.20 (0.99–1.47) 0.07 1.17 (1.02–1.34) 0.02
Diabetes mellitus
Multivariable 1.42 (1.12–1.81) 0.004 0.93 (0.77–1.13) 0.47 0.76 (0.62–0.93) 0.007 0.79 (0.66–0.93) 0.005
þBMI 0.99 (0.75–1.29) 0.91 0.69 (0.55–0.85) 0.0007 0.65 (0.52–0.82) 0.0002 0.62 (0.51–0.76) <0.0001
þFat volume* 0.43 (0.29–0.65) <0.0001 0.46 (0.35–0.60) <0.0001 0.55 (0.43–0.69) <0.0001 0.54 (0.44–0.66) <0.0001
Metabolic syndrome
Multivariable 3.65 (3.08–4.32) <0.0001 2.90 (2.52–3.34) <0.0001 1.68 (1.42–1.98) <0.0001 1.80 (1.57–2.06) <0.0001
þBMI 2.51 (2.09–3.01) <0.0001 2.21 (1.89–2.58) <0.0001 1.47 (1.19–1.82) 0.0003 1.33 (1.14–1.55) 0.0003
þFat volume* 1.53 (1.20–1.95) 0.0006 1.45 (1.20–1.74) 0.0001 1.06 (0.88–1.29) 0.53 1.08 (0.93–1.26) 0.32
Insulin resistancey
Multivariable 3.36 (2.82–3.99) <0.0001 3.02 (2.54–3.60) <0.0001 1.87 (1.54–2.28) <0.0001 1.94 (1.64–2.31) <0.0001
þBMI 2.27 (1.88–2.74) <0.0001 2.26 (1.87–2.74) <0.0001 1.51 (1.19–1.91) 0.0008 1.33 (1.10–1.61) 0.004
þFat volume* 1.46 (1.13–1.89) 0.003 1.56 (1.24–1.95) 0.0001 1.15 (0.92–1.44) 0.21 1.12 (0.92–1.35) 0.26
Values are odds ratios (OR) with 95% CIs per 1-SD decrease in HU. The p values for sex interaction for VAT HU: hypertension (p¼ 0.43), impaired fasting glucose (FG) (p¼ 0.0009), diabetes mellitus (p¼
0.01), metabolic syndrome (p ¼ 0.06), and insulin resistance (p ¼ 0.29). The p values for sex interaction for SAT HU: hypertension (p ¼ 0.34), impaired fasting glucose (p ¼ 0.22), diabetes (p ¼ 0.92),
metabolic syndrome (p¼ 0.11), and insulin resistance (p¼ 0.44). *VAT-HU regressions adjusted for VAT volume; SAT-HU regressions adjusted for SAT volume. yAmong nondiabetes participants with
available HOMA-IR data. Blood pressure indices were also adjusted for hypertension treatment; glycemic measures were also adjusted for diabetes treatment.
Abbreviations as in Table 1.
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768of inﬂammation in fat tissue and the role of macro-
phage accumulation (8,11–14) in worsening car-
diometabolic risk. Our study advances the literature
in several important ways. First, we present a
noninvasive, qualitative approach to the study of fat
distribution. Second, we present an association be-
tween a qualitative fat measure andmetabolic risk in a
large, well-deﬁned human cohort. Finally, this novel
approach to the study of fat distribution is associated
with cardiometabolic risk above and beyond quanti-
ﬁcation of fat volumes alone.
Potential physiological mechanisms. There are
several potential mechanisms to explain the associ-
ations of lower HU in both VAT and SAT depots
with more adverse metabolic risk factor levels. First,
lower HU is a marker of more lipid-dense fat tissue
(17). Furthermore, cellular lipid content helps to
determine adipocyte size (33), with large, mature
adipoctyes ﬁlled almost entirely by large lipid
droplets (34). In turn, adipocyte volume is a deter-
minant of the cell’s functionality, with larger adi-
pocytes predicting more adverse cardiometabolicrisk (7,9). As excess energy accumulates, it is stored
in fat depots, which undergo constant remodeling to
accommodate for changing fuel stores (35). Several
decades ago, fat-distribution studies determined
that persons with adipocyte hypertrophy were at risk
for adverse cardiometabolic outcomes (6), which has
been corroborated with more recent ﬁndings that
have demonstrated an inverse correlation between
mean adipocyte size, insulin sensitivity (7), and
adiponectin secretion (9). The reason for this
remains uncertain, but adipocyte hypertrophy may
be a compensatory mechanism in the overﬂow of
fatty acids (9) and result in the accommodation of
fuel surplus. Thus, it is possible that fat tissue with
lower attenuation on CT scans represents more
lipid-laden fat tissue, which may be a marker of
adipocyte hypertrophy.
In addition to lipid content, HU may also reﬂect
tissue vascularity. Highly vascularized tissue appears
less negative on CT studies due to the tissue prop-
erties of blood (36). This concept has been exploited
in the area of brown fat quantiﬁcation, as brown fat
AB
Figure 2. Associations of HU Within Tertiles of Absolute Levels of VAT
Associations of HU (fat density) within tertiles of absolute levels of VAT for (A) women and for (B)men. In women, the cutpoint between tertile
HU 1 and tertile HU 2 was 94.7. The cutpoint between tertile HU 2 and tertile HU 3 was 90.1. In men, the cutpoint between tertile HU 1 and
tertile HU 2 was 97.7. The cutpoint between tertile HU 2 and tertile HU 3 was 93.9. VAT1 represented the lowest tertile of VAT volume,
and VAT3 represented the highest tertile of VAT volume. Pink bars ¼ HU1; green bars ¼ HU2; and yellow bars ¼ HU3. *p < 0.05; ** p < 0.01;
***p < 0.001. HDL ¼ high-density lipoprotein; other abbreviations as in Figure 1.
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770corresponds to less negative HU (17,18). It has been
hypothesized that the relatively less negative HU that
characterizes brown fat is due to the higher vascularity
of this tissue bed (18). In addition, several recent
studies have highlighted a role of angiogenesis
(10,15) and vascular function (12,14) in association
with dysfunctional adipose tissue. A recent study of
human SAT and VAT demonstrated lower levels of
angiogenesis in association with increased adipose
tissue volume and increased BMI (15). Studies have
also implicated adipocyte hypertrophy in relation to
vascularity, demonstrating a decrease in capillary
density and angiogenic potential (10) in tissues with
increasing adipocyte size. These studies have sug-
gested that, ultimately, this decrease in perfusionmay
lead to hypoxia and inﬂammation of the adipose tis-
sue (10,15). Taken together, these experimental
ﬁndings raise the interesting possibility that lower
HU may additionally be a marker of adipose tissue
vascularity.
Implications for further research. Our ﬁndings
highlight the importance of applying both qualita-
tive and quantitative methods to the study of body
fat distribution, as these complementary methods
identiﬁed areas of fat with risk above and beyond
that predicted by fat volume alone. It remains un-
certain as to the mechanism linking lower HU in
both VAT and SAT to more adverse metabolic risk.
Thus, future research on this topic, particularly
studies that correlate imaging to fat histology and
macrophage accumulation, should help to determine
the underlying pathophysiology, which may ulti-
mately shed further light on the metabolic sequelae
of obesity.
Study strengths and limitations. Strengths include a
large, well-deﬁned cohort with rich phenotyping.
Some limitations warrant mention. As our sample is
predominantly of European ancestry, generaliz-
ability to other ethnicities is uncertain. Our study
design is observational and cross-sectional, limiting
inferences of temporality and causality. In addition,
increased BMI has been associated with increasedCT photon absorption, which would bias the CT
results in persons with higher BMI toward a higher
HU. Thus, our results may actually underestimate
the true magnitude of the association between lower
HU and cardiometabolic outcomes. There is also
the consideration of collinearity because persons
with larger fat volumes have lower CT attenuation.
However, after adjustment for fat volume, we found
that results were attenuated but not abolished,
suggesting a residual association of fat attenuation
with metabolic risk factors even after accounting for
absolute volume. The CT reconstruction algorithms
incorporate corrections for beam hardening that are
based on assumptions of the expected soft tissue
composition. As tissue composition varies in indi-
vidual persons, in some cases the measured attenu-
ation could be lower or higher than the actual
attenuation. However, if and how much this effec-
ted our data remains unknown. The ﬁndings of our
study, while statistically signiﬁcant, represent clini-
cally small effect sizes in risk factors and are illus-
trative of the multifactorial nature of obesity-related
complications. Finally, the mechanisms underlying
the association between HU and metabolic risk
remain speculative; further research will be necessary
to uncover the underlying fat tissue characteristics
captured by the variation in CT attenuation.
CONCLUS IONS
Fat quality, as measured by tissue attenuation on
CT, is associated with metabolic risk factors above
and beyond generalized adiposity and ectopic fat
tissue volume. These ﬁndings provide a unique,
novel framework by which to interpret CT imaging
of fat depots and may potentially add to our un-
derstanding of the metabolic sequelae of obesity.
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